Valeant reduces Q2 loss, revenue falls amid divestments

Valeant reduces Q2 loss, revenue falls amid divestments


Valeant Pharmaceuticals International says its second-quarter loss was reduced dramatically to US$38 million as the company progressed on its debt-reduction and divestment programs. That's down from the year-earlier loss of 88 cents per share or $302 million for the 2016 second quarter.



from Biotech News